Graphite Digital's 2026 research with 225 senior clinicians in the UK, US and Germany found 65% have reduced or stopped engaging with a pharma company after a poor digital experience. It is rarely a content problem. It is usually a segmentation problem: right message, wrong clinician, wrong moment.
HCP segmentation, also called healthcare professional segmentation, divides the prescriber universe into groups that behave differently and therefore deserve different treatment. A useful segment is defined by behaviour, not just specialty or decile rank.
A working HCP segmentation model answers three questions for every physician:
- Value: how much patient opportunity sits in this practice?
- Behaviour: how do they adopt, switch and where do they get evidence?
- Receptivity: which channel, cadence and message will they accept?
The field force is one of the largest controllable lines in a commercial P&L. Digital reach is cheap enough that the real constraint is clinician attention, not budget.
| Signal |
Finding |
| Volume fatigue |
52% receive too many messages from pharma brands |
| Tone mismatch |
52% find communications too promotional, not useful |
| Control |
59% want more say over what they receive and how often |
| Self-service |
55% prefer to find information themselves, when needed |
Source: Graphite Digital, 2026.
Segmentation turns that pressure into a plan: who to reach, who to leave alone, who to serve with pull rather than push.
Did you know?
IQVIA found HCP digital behaviour in obesity follows a long tail: a small top decile drives a disproportionate share of research activity, while most engage lightly. Segmentation exists because averages hide that curve.
Most HCP segmentation frameworks move through five stages:
- Define the commercial question: Launch adoption, share defence and portfolio expansion need different cuts.
- Resolve the data: Match Rx, claims, CRM and digital signals to one HCP identity, usually at NPI level.
- Engineer behavioural features: Adoption speed, switching, patient mix, channel response, referral position.
- Build and test segments: Cluster, then check segments are distinct, sizeable and stable.
- Activate and measure: Push segments into CRM, then track whether behaviour shifts.
|
HCP segmentation |
HCP targeting |
| Question |
Who are the distinct groups? |
Which individuals do we engage now? |
| Output |
Segment definitions and profiles |
Prioritised call and campaign lists |
| Horizon |
Strategic, refreshed periodically |
Tactical, refreshed each cycle |
| Weakness |
Goes stale between refreshes |
Executes yesterday's strategy |
Most brands still lean on one of four methods: value or decile-based ranking by volume, adoption-based grouping by uptake speed, behavioural clustering on clinical drivers, or channel-preference grouping. Each has its place. Each has the same three failure modes.
- The refresh cycle is too slow: Segments built in Q1 describe history by Q3. A rising prescriber waits a year for reclassification while a competitor engages them.
- The output stops at a segment, not a decision: Reps get a tier, not a name. Managers get a list, not a reason. Strategy set at HQ rarely survives translation into who to call next Tuesday.
- The strategy layer and the execution layer never meet: Priorities live in a strategy deck. Call plans live in the CRM. Nothing propagates automatically from one to the other.
This is the seam AI-driven HCP segmentation exists to close: platforms that keep the value layer, behavioural signals and execution layer in constant sync, rather than refreshing once a year and hoping the field catches up. HCPPulse is Polestar Analytics' version of that approach, built specifically for pharma commercial teams.
HCPPulse is a commercial engagement platform for pharmaceutical and life sciences. It replaces annual segmentation with a live prioritisation layer that sits alongside your CRM and data rather than replacing them. A written commercial objective becomes weighted priorities that propagate into HCP prioritisation and rep queues. The output is not a tier, it is a named prescriber with the reason attached, ready to open the day.
Three shifts against traditional methods:
- Strategy as an input, not a filter: A plain-text field strategy becomes P1 to P4 target priorities automatically. No spreadsheet rebuild when the objective moves.
- Continuous re-scoring: CRM engagement, prescription patterns, patient journey and third-party data resolve into a 360-degree HCP profile that moves as the data moves.
- A name, with the reason: For instance, a rep sees the specific pulmonologist, two of three patients already switched, last contact 41 days ago, not a percentage of tier-1 targets met.
HCPPulse gives the sales organisation the tools to be significantly more effective, with prebuilt KPIs and connectors that take a team from kickoff to live in six to eight weeks. Behind it sits Polestar Analytics' deep rare disease commercial pharma experience, a real differentiator in specialty engagement.
For the wider category context, our blog on AI in pharma covers where this shift is heading next.
To see it in action, watch the HCPPulse explainer: a written strategy turning into a ranked prescriber queue in minutes.
No system's data is ever fully clean, and waiting for it costs the field a full cycle. Most engagements resolve what exists into a working commercial pharma analytics view first, then layer in harder sources later, so a live view ships in weeks, not after a cleanup project.
Targeting executes a strategy already set; segmentation defines it. HCPPulse connects the two, turning a plain-text commercial objective into weighted P1 to P4 priorities that flow straight into Veeva-based call queues, closing the gap between the strategy deck and the CRM.
The heavier lift is upfront: one data model and one set of KPI definitions, not per-brand rebuilds. Once that's in place, adding a brand or geography is largely a configuration exercise, not a second implementation.